Survodutide (10mg)

A single-component research material supplied for controlled research environments. Suitable for studies involving dual agonist pathway characterization of glucagon receptors, receptor-binding assays, and method development in model systems.

Composition

• Survodutide
• Appearance: Lyophilized powder in a sealed research vial

Research Focus (non-clinical)

• Identity and purity assessment via HPLC/LC-MS
• Assay development for glucagon receptor models (e.g., binding and cell-based workflows)
• Chromatographic method optimization for variant and impurity profiling
• Stability characterization of a lyophilized peptide under laboratory storage conditions

For qualified research professionals and institutional laboratories. Not for human use.

Documentation & Quality Assurance

Each lot is sourced through our verified global supply chain with emphasis on traceability and quality control. We work diligently to obtain and maintain third-party analytical reports (HPLC/LC-MS) and Certificates of Analysis for each batch, as part of our ongoing quality process. These documents are reviewed internally and displayed as they become available. Independent third-party testing is also performed on select lots to confirm identity, purity, and alignment with our internal specifications.

Important Notice

This product is intended for laboratory research use only. It is not intended for human or veterinary use, and must not be used for diagnostic, therapeutic, or clinical purposes.
This material is not a drug, medical device, or dietary supplement, and has not been evaluated by the U.S. Food and Drug Administration.

Quality & Manufacturing

All materials are sourced from carefully vetted domestic and international manufacturing partners who follow quality systems consistent with ISO and cGMP principles. Each supplier is reviewed for reliability, documentation integrity, and transparency in testing.

We require a verified purity of 99% or higher and perform independent third-party spot testing to confirm that select lots meet our internal standards for identity, purity, and composition. Where available, endotoxin testing results are included on Certificates of Analysis to verify laboratory purity; their inclusion is for research quality assessment only and does not imply suitability for human or veterinary use.

All research materials are sealed for integrity and packaged for stability during storage and transport from manufacturing through final delivery.

What It Is

Survodutide (BI 456906) is a synthetic, acylated 29-amino-acid peptide derived from a modified glucagon sequence, engineered to achieve balanced co-agonism at both the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), with a C18 di-acid fatty acid chain appended at position 24 via a glycine-serine linker to extend plasma half-life through albumin binding.

Research Background

Survodutide was initially characterized through a series of in vitro assays using Chinese hamster ovary (CHO)-K1 cells expressing human GLP-1R and GCGR, mouse insulinoma MIN6 cells, rat primary hepatocytes, and human pancreatic islets. In vivo preclinical investigations were conducted in lean C57BL6/J mice, GLP-1R knockout mice, and diet-induced obese (DIO) mice on high-fat diet, employing indirect calorimetry, EchoMRI body-composition analysis, and bulk liver mRNA sequencing to assess pharmacodynamic effects. in Diabetes, Obesity and Metabolism further described pharmacological profiling using DIO and diabetic db/db mouse models alongside biomarker panels including FGF-21 plasma levels and hepatic NNMT mRNA expression as translational readouts of GCGR engagement. Clinical investigation progressed to a Phase II, multicentre, randomised, double-blind, placebo-controlled trial in 413 adults with type 2 diabetes, examining dose-response relationships over 16 weeks, with HbA1c change from baseline as the primary endpoint and relative bodyweight change as a key secondary endpoint.

Observed Areas of Interest in Research

Preclinical studies examined the compound's capacity to activate GLP-1R-dependent pathways — confirmed through dose-dependent food intake reduction and glucose tolerance improvement observed in wild-type but not GLP-1R knockout mice — alongside GCGR-dependent pathways evidenced by dose-dependent increases in plasma FGF-21 and upregulation of hepatic nicotinamide N-methyltransferase (NNMT) mRNA. Researchers also investigated hepatic energy metabolism at the transcriptional level, identifying 93 differentially expressed genes regulated by BI 456906 but not by selective GLP-1R agonists, involving pathways associated with the methionine cycle, oxidative phosphorylation, cholesterol metabolism, and GPCR signaling. CRE-luciferase bioluminescence imaging in transgenic mice demonstrated simultaneous activation of cAMP signaling in both pancreatic (GLP-1R) and hepatic (GCGR) compartments, a dual-organ engagement pattern distinguishing the compound from single-receptor reference compounds. In the Phase II clinical study, researchers measured changes in glycated hemoglobin, bodyweight, and related cardiometabolic parameters across multiple dose cohorts to characterize the dose-response profile of the compound's dual-receptor pharmacology under controlled conditions in a human population.

Research Notes

Purity verified by third-party laboratory analysis (Certificate of Analysis available on request). Supplied strictly for in-vitro and laboratory research use only. Not for human consumption.

All information above is provided for research and educational reference only and summarizes findings from published scientific literature (predominantly in-vitro and animal models). It does not describe outcomes in humans. This product is not a drug, dietary supplement, or article intended for human or veterinary use.

All products from Blitz Health are manufactured using a lyophilization (freeze-drying) process. This method is designed to maintain product integrity and allows vials to remain stable during shipping for approximately 3–4 months.

Once a vial is reconstituted with bacteriostatic water, it should be stored in the refrigerator to help maintain stability. Under these conditions, reconstituted material is generally considered stable for up to 30 days.

Lyophilization is a dehydration technique in which compounds are frozen and then exposed to low pressure. This causes the water in the vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure. This powder can be kept at room temperature until reconstitution.

Upon receipt, products should be stored away from heat and light. For short-term use, refrigeration at approximately 4°C (39°F) is suitable. For long-term storage (several months to years), vials may be placed in a freezer at approximately -80°C (-112°F). Freezing is the preferred method for preserving product stability over extended periods.

⚠️ Important Notice:
These products are intended for research use only. Not for human consumption.